Other research analysts also recently issued reports about the company. Credit Suisse Group set a CHF 260 price target on Roche and gave the company a neutral rating in a report on Monday, October 16th. Baader Bank set a CHF 231 price target on Roche and gave the company a neutral rating in a report on Thursday, October 19th. Morgan Stanley set a CHF 260 price target on Roche and gave the company a neutral rating in a report on Friday, December 8th. set a CHF 210 price target on Roche and gave the company a sell rating in a report on Monday, September 18th. Finally, Kepler Capital Markets set a CHF 230 price target on Roche and gave the company a neutral rating in a report on Monday, September 11th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of CHF 261.84.
Roche (VTX ROG) traded up CHF 2.40 during trading hours on Thursday, reaching CHF 244.10. The company had a trading volume of 6,110,000 shares, compared to its average volume of 1,710,000. Roche has a 52-week low of CHF 226.10 and a 52-week high of CHF 273.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.